News Column

Study Data from ICREA Provide New Insights into Gene Therapy (Short-Fiber Protein of Ad40 Confers Enteric Tropism and Protection Against Acidic...

July 17, 2014



Study Data from ICREA Provide New Insights into Gene Therapy (Short-Fiber Protein of Ad40 Confers Enteric Tropism and Protection Against Acidic Gastrointestinal Conditions)

By a News Reporter-Staff News Editor at Gene Therapy Weekly -- Data detailed on Biotechnology have been presented. According to news reporting originating from Barcelona, Spain, by NewsRx correspondents, research stated, "The lack of vectors for selective gene delivery to the intestine has hampered the development of gene therapy strategies for intestinal diseases. We hypothesized that chimeric adenoviruses of Ad5 (species C) displaying proteins of the naturally enteric Ad40 (species F) might hold the intestinal tropism of the species F and thus be useful for gene delivery to the intestine."

Our news editors obtained a quote from the research from ICREA, "As oral-fecal dissemination of enteric adenovirus must withstand the conditions encountered in the gastrointestinal tract, we studied the resistance of chimeric Ad5 carrying the short-fiber protein of Ad40 to acid milieu and proteases and found that the Ad40 short fiber confers resistance to inactivation in acidic conditions and that AdF/40S was further activated upon exposure to low pH. In contrast, the chimeric AdF/40S exhibited only a slightly higher protease resistance compared with Ad5 to proteases present in simulated gastric juice. Then, the biodistribution of different chimeric adenoviruses by oral, rectal, and intravenous routes was tested. Expression of reporter beta-galactosidase was measured in extracts of 15 different organs 3 days after administration. Our results indicate that among the chimeric viruses, only intrarectally given AdF/40S infected the colon (preferentially enteroendocrine cells and macrophages) and to a lesser extent, the small intestine, whereas Ad5 infectivity was very poor in all tissues. Additional in vitro experiments showed improved infectivity of AdF/40S also in different human epithelial cell lines."

According to the news editors, the research concluded: "Therefore, our results point at the chimeric adenovirus AdF/40S as an interesting vector for selective gene delivery to treat intestinal diseases."

For more information on this research see: Short-Fiber Protein of Ad40 Confers Enteric Tropism and Protection Against Acidic Gastrointestinal Conditions. Human Gene Therapy Methods, 2013;24(4):195-204. Human Gene Therapy Methods can be contacted at: Mary Ann Liebert, Inc, 140 Huguenot Street, 3RD Fl, New Rochelle, NY 10801, USA (see also Biotechnology).

The news editors report that additional information may be obtained by contacting E. Rodriguez, Inst Catalana Recerca & Estudis Avancats ICREA, Barcelona 08010, Spain. Additional authors for this research include C. Romero, A. Rio, M. Miralles, A. Raventos, L. Planells, J.F. Burgueno, H. Hamada, J.C. Perales, A. Bosch, M.A. Gassull, E. Fernandez and M. Chillon.

Keywords for this news article include: Biotechnology, Spain, Europe, Protease, Barcelona, Gene Therapy, Bioengineering, Gastroenterology, Enzymes and Coenzymes

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Gene Therapy Weekly


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters